General Information of the Compound
Compound ID |
CP0056017
|
||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Compound Name |
α-CA inhibitor, 12
Show/Hide
|
||||||||||||||||||
Synonyms |
1,2-benzenediol
1,2-dihydroxybenzene
120-80-9
2-hydroxyphenol
Benzene, o-dihydroxy-
C.I. Oxidation Base 26
CATECHOL
Catechin (phenol)
Catechol (phenol)
Durafur developer C
Fouramine PCH
Fourrine 68
Katechol
Oxyphenic acid
Pelagol Grey C
Phthalhydroquinone
Pyrocatechine
Pyrokatechin
Pyrokatechol
benzene-1,2-diol
benzenediol
o-Benzenediol
o-Dihydroxybenzene
o-Dioxybenzene
o-Diphenol
o-Hydroquinone
o-Hydroxyphenol
o-Phenylenediol
ortho-Dihydroxybenzene
ortho-Hydroxyphenol
pyrocatechin
pyrocatechol
Show/Hide
|
||||||||||||||||||
Structure |
|
||||||||||||||||||
Formula |
C6H6O2
|
||||||||||||||||||
Molecular Weight |
110.112
|
||||||||||||||||||
Canonical SMILES |
Oc1ccccc1O
Show/Hide
|
||||||||||||||||||
InChI |
InChI=1S/C6H6O2/c7-5-3-1-2-4-6(5)8/h1-4,7-8H
Show/Hide
|
||||||||||||||||||
InChIKey |
YCIMNLLNPGFGHC-UHFFFAOYSA-N
|
||||||||||||||||||
CAS |
37349-32-9
16474-90-1
16474-89-8
12385-08-9
120-80-9
|
||||||||||||||||||
Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
PubChem ID | |||||||||||||||||||
ChEMBL ID | |||||||||||||||||||
DrugBank ID |
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT02997, Isocitrate dehydrogenase [NADP] cytoplasmic
Protein ID: PT01065, Serine/threonine-protein kinase mTOR
Clinical Information about the Compound